Zona Occludens-2 Inhibits Cyclin D1 Expression and Cell Proliferation and Exhibits Changes in Localization along the Cell Cycle

Rocio Tapia,* Miriam Huerta,† Socorro Islas,* Antonia Avila-Flores,‡ Esther Lopez-Bayghen,† Jörg Weiske,§ Otmar Huber,§| and Lorenza González-Mariscal*

*Department of Physiology, Biophysics, and Neuroscience, and †Department of Genetics and Molecular Biology, Center for Research and Advanced Studies (CINVESTAV), Mexico, D.F., 07360, Mexico; ‡Department of Immunology and Oncology, National Center for Biotechnology, Consejo Superior de Investigaciones Científicas, Campus Cantoblanco, E-28049 Madrid, Spain; §Department of Laboratory Medicine and Pathobioc hemistry, Charité-Universitätsmedizin Berlin, 12200 Berlin, Germany; and ||Department of Biochemistry II, Friedrich-Schiller-University Jena, 07743 Jena, Germany

Submitted March 14, 2008; Revised October 28, 2008; Accepted November 21, 2008
Monitoring Editor: Keith E. Mostov

Here, we have studied the effect of the tight junction protein zona occludens (ZO)-2 on cyclin D1 (CD1) protein expression. CD1 is essential for cell progression through the G1 phase of the cell cycle. We have found that in cultures of synchronized Madin-Darby canine kidney cells, ZO-2 inhibits cell proliferation at G0/G1 and decreases CD1 protein level. These effects occur in response to a diminished CD1 translation and an augmented CD1 degradation at the proteosome triggered by ZO-2. ZO-2 overexpression decreases the amount of Glycogen synthase kinase-3β phosphorylated at Ser9 and represses β-catenin target gene expression. We have also explored the expression of ZO-2 through the cell cycle and demonstrate that ZO-2 enters the nucleus at the late G1 phase and leaves the nucleus when the cell is in mitosis. These results thus explain why in confluent quiescent epithelia ZO-2 is absent from the nucleus and localizes at the cellular borders, whereas in sparse proliferating cultures ZO-2 is conspicuously present at the nucleus.

INTRODUCTION

Epithelial sheets constitute the frontier between the external environment and the internal milieu in multicellular organisms. Epithelial cells attach to each other by a group of intercellular contacts. At the uppermost portion of the lateral membrane, the paracellular space is sealed by tight junctions (TJs). This structure performs two crucial functions in epithelial cells: it both regulates the transit of ions and molecules via the intercellular space and maintains a polarized distribution of lipids and proteins between the apical and basolateral domains, by blocking their free diffusion within the plasma membrane.

The TJ is constituted by transmembrane and adaptor proteins. Although the former establish cell–cell contact through their extracellular domains, the latter work as scaffolds that reunite at a specific region of the membrane, a complex set of proteins that includes kinases, phosphatases, transcription factors (TFs), and small guanosine triphosphate-binding proteins, among others (for a review on TJ proteins, see Gonzalez-Mariscal et al., 2000).}

ZO-2 is a member of the membrane associated guanylate kinase homologous protein family (MAGUK) (Gumbiner et al., 1991). All identified family members include characteristic postsynaptic density 95/disc-large/zona occludens (PDZ), Src homology 3 (SH3) and guanylate kinase-like (GK) domains, all of them known to be involved in protein–protein interactions (Gonzalez-Mariscal et al., 2000).}

Junctional proteins not only exert functions related to their barrier role at the plasma membrane but also are involved in signal transduction, transferring information to the cell interior to modulate cell proliferation and differentiation (Balda et al., 2003; Sourisseau et al., 2006). First evidence that this role may be attributed to ZO proteins was given from their high homology to the tumor suppressor protein DlgA (Willott et al., 1993; Woods et al., 1997). This notion has been further supported by the observation that in several carcinomas the expression of junctional proteins is down-regulated (for review, see Gonzalez-Mariscal et al., 2007) as shown for ZO-2 in breast and pancreatic cancer (Chlenski et al., 1999, 2000).

Furthermore, ZO-2 has been found to be a target for viral oncoproteins. Hence, the transforming potential of the adenovirus type 9 oncogenic determinant E4 (Ad9 E4-ORF1) is associated with its ability to bind and aberrantly sequester ZO-2 within the cytoplasm, whereas the overexpression of ZO-2 inhibits Ad9 E4-ORF1–induced transformation (Glaunsinger et al., 2001; Latorre et al., 2005).

The subcellular distribution of ZO-2 is responsive to the degree of cell–cell contact. Thus in confluent epithelial
monolayers, ZO-2 localizes at the TJ, whereas in sparse cultures characterized for their high proliferative state, a significant amount of ZO-2 concentrates in the nucleus (Islas et al., 2002). There, ZO-2 associates to the nuclear matrix (Jaramillo et al., 2004), displays a speckled distribution, and colocalizes with the essential splicing factor SC-35 (Islas et al., 2002), and with the nuclear scaffold attachment factor SAF-B (Traweger et al., 2003), a corepressor of estrogen receptor-α known to regulate the transcription of genes involved in proliferation, apoptosis, and migration. For its movement in and out of the nucleus, four nuclear localization and five export signals have been identified previously (Ilsas et al., 2002; Jaramillo et al., 2004; Gonzalez-Mariscal et al., 2006).

In a previous work, we demonstrated the specific interaction of ZO-2 with Jun and Fos TFs, which form a transcription complex named AP-1 (Betanzos et al., 2004). Because AP-1 is involved in cell proliferation, transformation, and death (Shaulian and Karin, 2002), we explored the impact of ZO-2 expression on the activity of the CD1 promoter, and observed that ZO-2 down-regulates CD1 transcription by interacting with the c-Myc/E box element and by recruiting histone deacetylases (Huerta et al., 2007).

CD1 is rate limiting and essential for cell progression through the G1 phase of the cell cycle. CD1 binds to and activates the cyclin-dependent kinases Cdks4 and Cdks6, which in turn phosphorylate their downstream target the retinoblastoma protein (Rb). The latter binds to and negatively regulates the activities of E2F TFs. On Rb-dependent phosphorylation, E2F TFs are liberated and hence activate the expression of the S phase genes, thereby inducing cell cycle progression (Coqueret, 2002).

Here, we have analyzed the impact of ZO-2 overexpression on epithelial cell proliferation and CD1 expression. Our results indicate that ZO-2 overexpression inhibits cell proliferation by blocking progression of cells through the cell cycle at the G1/S boundary. ZO-2 decreases CD1 protein levels by diminishing its translation and increasing its degradation at the proteosome. In addition, we observed that the nuclear expression of ZO-2 varies with the cell cycle as ZO-2 enters the nucleus at the late stage of G1 and leaves the nucleus during mitosis.

MATERIALS AND METHODS

Cell Culture

Epithelial Madin-Darby canine kidney (MDCK) cells between the 60th and 90th passage were grown as described previously (Gonzalez-Mariscal et al., 1985). Cells were harvested with trypsin-EDTA and plated either sparse (1 × 10^5 cells/cm^2) or at confluence (3 × 10^5 cells/cm^2). The synchronized cultures in the sparse condition cells were plated at an initial density of 0.5 × 10^5 cells/cm^2. Human embryonic kidney (HEK) 293, SW480, and MCF-7 cells were cultured as described previously (Weiske and Huber, 2006).

Expression Plasmids, Small Interfering RNAs (siRNAs), and Transfection Assays

Full-length canine ZO-2 introduced into the cytomegalovirus expression plasmid pGW1 (pGW1-HA-ZO-2) was kindly provided by Ronald Javier (Baylor...
Colleage of Medicine, Houston, TX). The amino-terminal (NH₂-containing PDZ1, PDZ2, and PDZ3 domains; 398-2165 nucleotides [nt]), middle (3PSC, containing PDZ3, SH3, and GUK domains; 1593-3019 nt), and carboxy-termi-

nal (AP, containing the acidic and proline-rich domains; 3029–3923 nt) seg-

ments of canine ZO-2 were introduced into pcDNA4/HisMax as reported previously (Betanzos et al., 2004; Jaramillo et al., 2004). pc86-ZO-1myc was kindly provided by Dr. Maria Susana Balda (Institute of Ophthalmology, University College of London, London, United Kingdom).

Western blot gene assays were performed as described previously (Weiske et al., 2007). HEK293 cells (5 × 10⁵) were transfected in a Lumat LB9507 luminometer with an excitation of a 488-nm argon-ion laser line. The data were analyzed using the ModFitLT version 2.0 (PMac DNA content histogram deconvolution software.

<table>
<thead>
<tr>
<th>Transfection</th>
<th>Staurosporine</th>
<th>Viable cells (%)</th>
<th>Apoptotic early cells (%)</th>
<th>Apoptotic late cells (%)</th>
<th>Necrotic cells (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mock</td>
<td>92.80 ± 0.64</td>
<td>0.20 ± 0.05</td>
<td>0.98 ± 0.09</td>
<td>6.03 ± 0.69</td>
<td></td>
</tr>
<tr>
<td>0.5µM, 4h</td>
<td>79.14 ± 2.58</td>
<td>1.31 ± 0.07</td>
<td>7.53 ± 0.45</td>
<td>12.03 ± 2.21</td>
<td></td>
</tr>
<tr>
<td>1.0µM, 24h</td>
<td>16.65 ± 1.90</td>
<td>0.57 ± 0.04</td>
<td>49.20 ± 5.50</td>
<td>33.50 ± 4.90</td>
<td></td>
</tr>
<tr>
<td>pGW1</td>
<td>90.85 ± 1.57</td>
<td>0.33 ± 0.12</td>
<td>1.37 ± 0.52</td>
<td>7.47 ± 0.96</td>
<td></td>
</tr>
<tr>
<td>pGW1-HA-ZO-2</td>
<td>92.75 ± 1.0</td>
<td>0.22 ± 0.07</td>
<td>1.18 ± 0.26</td>
<td>5.85 ± 0.72</td>
<td></td>
</tr>
</tbody>
</table>

Spars MDCK cells were synchronized by serum starvation for 48 h. Then, they were incubated for 24 h in DMEM and transfected with the empty vector or pGW1-HA-ZO-2. Twenty-four hours later, apoptosis was determined by annexin V fluorescence and flow cytometry. A group of nontransfected cells was treated with staurosporine for a positive apoptosis control. Media ± SE were obtained with the values from four independent experiments.

Synchronization of Cell Cultures and Cell Cycle Analysis with Propidium Iodide

MDCK cells were plated at confluent or sparse density in DMEM (D1152; Sigma-Aldrich) with penicillin (100 IU/ml), streptomycin (100 µg/ml), and 10% (vol/vol) iron supplemented certified calf serum (10371-029; Invitrogen). After 24 h, the cells were transferred to DMEM containing 0.1% (vol/vol) of serum for 48 h (condition A in Figures 3 and 6). Cell cycle entry was then triggered by addition of 10% (vol/vol) serum (CDM) for 24 h (condition B in Figures 3 and 6). Next, a group of cells was transfected with pGW1-HA-ZO-2 or the empty vector and analyzed 24 h later (condition C in Figures 3 and 6). Alternatively, 48 h after serum starvation, the cells were transfected with pGW1-HA-ZO-2, His/Max-NH2-ZO-2, His/Max-3PS-CZO-ZO-2, His/Max-AP-ZO-2 or the corresponding empty vectors, and 6 h after transfection transferred to CDMEM. Then, 24 h later the cells were analyzed (condition D in Figures 3 and 6). In yet another experiment, the sparse and unsynchronized cells were transfected with pGW1-HA-ZO-2 or the empty vector, and 6 h after transfection they were submitted to serum deprivation (0.1% [vol/vol] serum) for 48 h (condition E in Figure 6).

For the determination of the percentage of cells present in each phase of the cell cycle a standard procedure was followed (Dasso, 1999). Briefly, the cells were trypsinized, fixed, and permeabilized in 70% (vol/vol) ice-cold ethanol to make them accessible to propidium iodide (PI). Once fixed, the cells were rinsed with PBS and stained with a PBS solution containing 1.0% (vol/vol) Triton X-100, 0.20 mg/ml DNase-free RNAse A, and 0.02 mg/ml PI. Triton X-100 was included to decrease the cell loss resulting from electrostatic cell attachment to tubes and the RNAse A to digest the double-stranded sections of RNA that might stain with PI. Measurements were done on a flow cytometer with an excitation of a 488-nm argon-ion laser line. The data were analyzed using the ModFitLT version 2.0 (PMac DNA content histogram deconvolution software.
Figure 3. Flow cytometric analysis reveals a blockade at G0/G1 in cells transfected with ZO-2. Sparse cells incubated for 48 h with 0.1% serum (A), and further cultured for 24 h with CDMEM (B), were transfected with ZO-2 or the empty vector. After 24 h, the cells were stained with PI, and a flow cytometric analysis was performed (C) to obtain the percentages of cells in each particular stage of the cell cycle. Sparse cells incubated for 48 h with 0.1% serum (A) and then transfected with full-length ZO-2, the amino-, middle, and carboxy-terminal segments of ZO-2 or the empty vectors were incubated 6 h after the transfection with CDMEM. After 24 h, the cells were stained with PI, and a flow cytometric analysis was performed (D) to obtain the percentages of cells in each particular stage of the cell cycle. The upper portion of the figure illustrates the protocols used, whereas the lower section shows representative histograms obtained for each condition. The letters A, B, C, and D indicate the time point at which the distribution of cells in the particular stages of the cell cycle was evaluated.
Cell Proliferation Assay

The entry into the 6 phase was quantified by determining the incorporation of [3H]thymidine. For this purpose, synchronized cells, transfected with pGW1-HA-ZO-2 or the empty vector, were incubated for 24 h with 0.45 μCi/ml [3H]thymidine. The incorporation was stopped with two washes with cold PBS, precipitation with 5% (wt/vol) trichloroacetic acid, and cells were lysed with 0.4 M NaOH. After 1 h of gentle agitation at room temperature, 100 μl of each sample was taken for protein quantification, and another 100 μl was solubilized in 25 μl of 10% (vol/vol) acetic acid, 400 μl of 0.4 M NaOH, and 2 ml of scintillation liquid. Samples were counted in a beta-scintillation counter (LS 6000 TA; Beckman Coulter, Fullerton, CA).

Cell Viability and Apoptosis Determination

The proportion of viable cells in the culture was determined using the vital stain trypan blue (Sigma-Aldrich), according to the manufacturer's instructions. Wild-type MDCK membrane was determined using the annexin V-FLUOS staining kit (Roche Diagnostics), according to the manufacturer's instructions. The annexin V-FLUOS staining kit is used to detect early and late apoptosis by quantifying the percentage of cells that have undergone membrane translocation of phosphatidylserine (PS) to the external surface of the membrane.

Immunofluorescence

Monolayers grown on glass coverslips were fixed with 2% (wt/vol) formaldehyde in PBS, pH 7.4, and permeabilized for 5 min with 0.1% (vol/vol) Triton X-100 in PBS. Cells were washed five times with PBS and then blocked for 30 min with 1% bovine serum albumin (lg-free) (1331-a; Research Organics, Cleveland, OH) containing 0.03% (wt/vol) saponin. The monolayers were incubated overnight at 4°C with rabbit polyclonal anti-ZO-2 antibodies (71-1400; Zymed Laboratories) (diluted 1:100) or anti-CD1 (Sc-717; Santa Cruz Biotechnology) (diluted 1:50).

Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR)

Total RNA was extracted from cells using the TRIzol reagent (Invitrogen). Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) was performed by a two-step method. cDNA was generated from 1 μg of total RNA by ImProm-II reverse transcription system (Promega) with oligo(dT)15 as a primer according to the manufacturer's instruction. Real-time PCR was performed using the QuantiTect SYBR Green PCR kit (204143; QIAGEN, Hilden, Germany) in a volume of 25 μl. Triplicate samples were subjected to qPCR by using the 7300 Real-Time PCR System (Applied Biosystems, Foster City, CA), with the maximum cycle number of 40. Actin was used as an internal control. The relative abundance of cyclin D1 gene expression was calculated. Two independent batches of RNA samples were used for qRT-PCR analysis, and data were presented as mean ± SE and analyzed by Student’s t test.

The proportion of cells found at the different stages of the cell cycle was evaluated, according to the protocol illustrated in the diagram of Figure 3. Cells evaluated at the C and D condition were transfected with pGW1-HA-ZO-2 or the empty vector. Media ± SE were obtained with the values from four independent experiments (*p < 0.05; **p < 0.01, and ***p = 0.001; ANOVA Tukey’s multiple comparison test).

Table 2. Percentage of cells found at the different stages of the cell cycle in synchronized cultures transfected with full length ZO-2 or with ZO-2 segments

<table>
<thead>
<tr>
<th>Cell cycle stage</th>
<th>C (%)</th>
<th>D (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A (%)</td>
<td>B (%)</td>
<td>pGW1-HA-ZO-2</td>
</tr>
<tr>
<td>G0/G1</td>
<td>73 ± 0.19</td>
<td>48 ± 3.0</td>
</tr>
<tr>
<td>S</td>
<td>16 ± 0.37</td>
<td>23 ± 1.0</td>
</tr>
<tr>
<td>G2/M</td>
<td>11 ± 0.36</td>
<td>29 ± 3.0</td>
</tr>
</tbody>
</table>

The letters A, B, C, and D indicate the moment at which the distribution of cells in the particular stages of the cell cycle was evaluated, according to the protocol illustrated in the diagram of Figure 3. The letters A, B, C, and D indicate the moment at which the distribution of cells in the particular stages of the cell cycle was evaluated. The distribution of cells in the particular stages of the cell cycle was evaluated, according to the protocol illustrated in the diagram of Figure 3. The letters A, B, C, and D indicate the moment at which the distribution of cells in the particular stages of the cell cycle was evaluated, according to the protocol illustrated in the diagram of Figure 3. The letters A, B, C, and D indicate the moment at which the distribution of cells in the particular stages of the cell cycle was evaluated, according to the protocol illustrated in the diagram of Figure 3. The letters A, B, C, and D indicate the moment at which the distribution of cells in the particular stages of the cell cycle was evaluated, according to the protocol illustrated in the diagram of Figure 3.
used to CD1 immunoprecipitation. Immunoprecipitates were resolved on 12% SDS-polyacrylamide gel electrophoresis (PAGE) gels and 35S-labeled proteins were detected on dried gels and quantified using the Personal Molecular Imager FX phosphorimaging system (Bio-Rad, Hercules, CA).

**Analysis of CD1 Stability**

Sparse cultures of MDCK cells synchronized by serum starvation for 48 h were transfected with full-length ZO-2; His-NH2-ZO-2 construct; full-length ZO-1; the corresponding empty vectors pGW1, His/MaxB, and pCB6; or ZO-2 siRNA and the negative control NC. After 24 h, the cells were incubated in methionine- and cysteine-free DMEM containing 4 mM glutamine, 5 \( \mu \)g/ml insulin, and 5\% (vol/vol) dialyzed fetal bovine serum for 30 min and then labeled with 100 \( \mu \)Ci of Easy Tag Express protein labeling mix \([35S]\text{Met/Cys}\). 

To determine the rate of turnover of CD1, the radioactive medium was removed 1 h after addition, and the cells were then rapidly washed with a large volume of CDMEM and incubated for different chase periods (45, 60, 90, and 120 min) at 37°C with CDMEM containing 50 \( \mu \)g/ml cycloheximide an inhibitor of protein synthesis. The cells were next harvested for CD1 immunoprecipitation and the immunoprecipitates were resolved on 12% SDS-PAGE gels. 35S-labeled proteins were detected on dried gels and quantified with the Personal Molecular Imager FX phosphorimaging system (Bio-Rad).

**Inhibition of Protein Degradation**

Sparse cells synchronized by serum starvation for 48 h and subsequently cultured in CDMEM for 24 h were transfected with pGW1-HA-ZO-2 or the empty vector. Eight hours later, the cells were treated for 16 h with 50 mM LiCl, an inhibitor of GSK-3\(\beta\). Alternatively, 19 h after transfection, the cultures were incubated for 5 h with 50 \( \mu \)M MG132, a proteasomal inhibitor, or 100 \( \mu \)M chloroquine, a lysosomal inhibitor. Then, the cells were lysed and processed for SDS-PAGE and blotted with specific antibodies against ZO-2, CD1, and actin.

**RESULTS**

**Overexpression of ZO-2 Down-Regulates Cyclin D1 Protein and Inhibits Cell Proliferation**

To investigate the role of ZO-2 on cell proliferation, epithelial cells were transfected with increasing amounts of ZO-2 expression vector, and changes in CD1 protein levels were analyzed by Western blotting (Figure 1). Concomitant with the increase of ZO-2 protein levels, the amount of CD1 protein decreases.

Next, we evaluated the impact of ZO-2 overexpression on cell proliferation. As shown in Figure 2A, in synchronized cultures of sparse cells, ZO-2 transfection inhibits \([3H]\text{thymidine incorporation, whereas no effect was detectable in confluent cultures, which as expected exhibited a low [3H]thymidine incorporation rate. The diminished incorporation of [3H]thymidine is not due to an increased rate of cell death, because ZO-2 transfection does not change the cell viability, as determined by trypan blue exclusion (Figure 2B). Moreover, ZO-2 transfection does not augment the percentage of necrotic, early, or late apoptotic cells in the culture (Table 1), as analyzed with an annexin assay by flow cytometry. In these experiments, staurosporine, a potent protein kinase C inhibitor (Tamaoki et al., 1986), frequently used as an apoptosis inducer (Nicotera et al., 1999; Zambrano et al., 2004), was included as a positive control for apoptosis induction.**

**Figure 4.** Release of synchronized cell cultures into the cell cycle changes the subcellular distribution of CD1 and ZO-2. Immunofluorescence microscopic detection of ZO-2 and CD1, and flow cytometric analysis were done in parallel at different times, indicated in the upper diagram, in serum-deprived cells and in those subsequently transferred to the normal growth media CDMEM. At least two independent experiments were performed for each time.
Figure 5.

A

CD1

No treatment | L-Minosine | WD 8h

ZO2

No treatment | L-Minosine | WD 8h

B

CD1

No treatment | Nocodazole | WD 9 min | WD 2 h

ZO2

No treatment | Nocodazole | WD 9 min | WD 2 h

Counts

 Channels

Counts

 Channels

Counts

 Channels

Counts

 Channels

Counts

 Channels

Counts

 Channels

Figure 5.
ZO-2 Overexpression Blocks Cell Cycle Progression
Because ZO-2 overexpression inhibits cell proliferation, we next explored in which stage of the cell cycle the cells were arrested. To test the impact of ZO-2 on cell cycle progression, we used two protocols using cell cultures synchronized by serum deprivation. The letters A, B, C, and D in Figure 3 indicate the time at which the cell cycle distribution of cells was evaluated by flow cytometric analysis. Figure 3 shows a representative example of the DNA content frequency histograms, whereas the values of three to seven independent experiments are summarized in Table 2.

After 48 h of incubation in media with 0.1% of serum 77% of cells were arrested at G0/G1 (condition A). The subsequent transfer for 24 h to CDMEM triggers the entry of the synchronized culture into the cell cycle, reducing the percentage of cells at G0/G1 to 41% (condition B). If at this point the cells are transfected with ZO-2, it was observed that 24 h later (condition C), the percentage of cells at G0/G1 further increases to 51%, whereas in control cells treated with empty vector, only 35% of cells were at G0/G1. In the second protocol, we transfected the cells with ZO-2 after 48 h of incubation in medium containing 0.1% serum (condition A) and before adding CDMEM for 24 h to the serum-deprived cultured cells. Under these conditions, the percentage of cells transfected with ZO-2 displayed a significantly higher amount of cells at G0/G1 than those transfected with the empty vector (81 vs. 41%; condition D). Together, these results indicate that the overexpression of ZO-2 inhibits the progression of cells through the cell cycle at the G1/S boundary.

Next, we analyzed which part of ZO-2 was responsible for inhibiting cell cycle progression. For this purpose, the monolayers following condition D were transfected with constructs encoding the amino-terminal (His-NH2-ZO-2), middle (His-3PSG-ZO-2), and carboxy-terminal (His-AP-ZO-2) segments of ZO-2, or with the corresponding empty vector (His/MaxB). Transfection with the middle and carboxy-terminal segments of ZO-2 exerted no significant effect. In contrast, transfection of the ZO-2 amino-terminal fragment increased the percentage of cells at G0/G1 in comparison with cultures transfected with the empty vector (61 vs. 47%).

Figure 6. ZO-2 overexpression exerts no effect on the level of CD1 mRNA in synchronized cultures. Quantitative RT-PCR experiments were performed at the times indicated with the letters A, C, D, and E in epithelial cells that were treated as schematically depicted in the upper portion of the figure. The results obtained with two independent experiments are presented in the lower histograms.

Figure 5 (cont). The nuclear distribution of ZO-2 and CD1 is sensitive to the cell cycle status. Immunofluorescence detection of ZO-2 and CD1 in (A) MDCK cells either not treated or treated with 1 mM 1-mimosine for 24 h. Subsequently, cells were either fixed or the drug was washed out and cells were incubated for further 6 h in normal growth media (CDMEM) and then fixed. (B) Cultures treated or untreated with 0.3 μM nocodazole for 16 h were treated as described above and then fixed after the drug had been washed out for different times. At the bottom part of each panel of this figure, a flow cytometric analysis reveals the percentages of cells found in each particular stage of the cell cycle. At least two independent experiments were done for each time point.
The value obtained is lower, albeit of no statistical difference to that obtained after transfection with full length ZO-2 (Table 2).

The Subcellular Localization of ZO-2 and Cyclin D1 Varies within the Cell Cycle

Next, we studied the subcellular distribution of CD1 in response to ZO-2 overexpression. Immunofluorescence microscopy (IF) did not reveal any changes in the nuclear localization of CD1 (data not shown). Therefore, in a next set of experiments, we decided to analyze the distribution of endogenous ZO-2 and cyclin D1 during the cell cycle. As illustrated in Figure 4, in cultures synchronized by serum starvation, transfer to CDMEM induces an increase in CD1 nuclear staining, as the cells moves through the cell cycle. This effect is even more evident for ZO-2 as in serum-deprived cells ZO-2 nuclear staining is low, whereas after 18 h a strong nuclear staining was detectable. Membrane staining of ZO-2 does no change through the cell cycle. To explore the location of CD1 and ZO-2 in a condition where a higher percentage of cells is in a particular phase of the cell cycle pharmacological agents were used. For this purpose, sparse nonsynchronized cells were treated with 1 mM l-mimosine, a plant amino acid derivative that blocks cell cycle progression in the late G1 phase (Krude, 1999). After a 24-h treatment with 1 mM l-mimosine, one group of cells was fixed and processed for immunofluorescence (IF) detection of ZO-2 and CD1, whereas in other monolayers the drug containing media was washed out, and incubation was continued in normal growth media for 6 h after which the IF procedure was performed. As shown in Figure 5A, in cultures treated with l-mimosine, 69% of the cells are at G1 phase. The IF observation shows a slight increase in CD1 nuclear staining and no obvious difference in the distribution and extent of nuclear ZO-2 in comparison with untreated cells. In contrast, 6 h after the washout of l-mimosine from the culture media, 71% of the cells are in the S phase and CD1 nuclear staining is no longer detectable, whereas ZO-2 is still present in the nucleus. Next, sparse unsynchronized cultures were treated for 16 h with 0.3 μM nocodazole. This agent arrests the cell cycle at the beginning of mitosis because it blocks spindle microtubule assembly but permits other mitotic events to proceed such as chromosome condensation and cell rounding (Hamilton and Snyder, 1982). Figure 5B illustrates that in cultures treated with nocodazole 98% of cells are at G2/M and ZO-2 exhibits a conspicuous nuclear staining, whereas the nuclear CD1 signal is low. After a 30-min washout, ZO-2 disappears from the nucleus. At this time, the percentage of cells that has reached the G0/G1 phase is still very low (7%), indicating that ZO-2 exits the nucleus at mitosis. Four hours after the nocodazole washout, CD1 is conspicuously present at the nucleus. Because FACS analysis revealed that at this time the percentage of cells at G0/G1 has increased to 73%, these results suggest that CD1 enters the nucleus at the early stages of G1. Nineteen hours after washout, when the percentage of cells at G0/G1 has diminished to 51% and that at S has increased to 30%, ZO-2 is present at the nucleus. This observation together with that obtained with mimosine treatment strongly suggests that ZO-2 enters the nucleus at the later stages of G1.

ZO-2 Overexpression Exerts No Effect on the Level of CD1 mRNA in Synchronized Cultures

Because the presence of CD1 is necessary for cell cycle progression through G1 to S phase we next explored, by quantitative RT-PCR, if ZO-2 transfection affected the amount of CD1 mRNA. The letters A, C, D, and E indicate the time at which the mRNA was harvested and qRT-PCR was performed for each experimental condition as schematically depicted in the diagram of Figure 6. Results obtained in two independent experiments are summarized in the lower histograms. Transfection of ZO-2 to a synchronized cell culture has no impact on the amount of CD1 mRNA (condition C) even if ZO-2 is transfected before the cells are switched to serum-containing media (condition D) (Figure 6). Interestingly, the amount of CD1 mRNA is higher in cells incubated for 48 h in 0.1% serum than in those cultured with CDMEM (condition A), and transfection of ZO-2 to cells that are subsequently incubated in serum-deprived media exerts no change in the amount of CD1 mRNA (condition E). Together, these results indicate that in cells

![Figure 7](image-url)
that have been synchronized by serum deprivation ZO-2 transfection exerts no effect on the level of CD1 mRNA in comparison with cultures transfected with the empty vector.

Figure 8. ZO-2 overexpression has no effect on the phosphorylation of mTOR and its targets p70 S6K and 4E-BP1. MDCK cells synchronized for 48 h by serum deprivation were incubated for 24 h in CDMEM and subsequently transfected with ZO-2 or the empty vector. After 24 h, the cells were lysed and processed for SDS-PAGE. Some cultures were treated with rapamycin (R) for 30 min before cell lysis. Western blots were done with antibodies against: mTOR and phosphorylated Ser2448 or Ser2481 of mTOR (A), p70 S6K and phosphorylated Thr389 and Thr421/Ser424 of p70 S6K (B), and 4E-BP1 and actin (C).
ZO-2 Overexpression Inhibits CD1 Synthesis

Because ZO-2 overexpression decreases the amount of CD1 protein present in MDCK cells, but exerts no effect on the level of CD1 mRNA, we proceeded to analyze the impact of ZO-2 on CD1 synthesis. For this purpose, [35S]Met/Cys labeling for different times was performed in cells transfected with ZO-2 or the empty vector pGW1 (condition D in Figure 3). As presented in Figure 7, a significantly lower radioactivity of immunoprecipitated CD1 in cells transfected with ZO-2 relative to those transfected with the empty vector at 90 and 120 min was detectable. Next, we analyzed whether these effects are specific for ZO-2. For such a purpose, the cells were transfected with ZO-1, another MAGUK TJ protein, and with a ZO-2 siRNA shown previously by us to specifically inhibit ZO-2 expression (Hernandez et al., 2007). As controls, cells were transfected with the empty vector pCB6 and NC, which correspond to a siRNA without any homology to any sequence in the vertebrate transcriptome. Figure 7 illustrates that ZO-2-induced effects upon CD1 de novo synthesis are specific because the overexpression of ZO-1 did not exert a comparable effect. Similarly depletion of ZO-2 by siRNA did not affect CD1 synthesis in accordance with previous results showing that ZO-2 silencing has no impact on cell proliferation (Hernandez et al., 2007).

Because transfection with the amino-terminal fragment of ZO-2 increases the percentage of cells at G0/G1, we next explored its impact on de novo CD1 synthesis. Cells transfected with His-NH$_2$-ZO-2 revealed a significantly lower radioactivity of immunoprecipitated CD1 in monolayers than cells in cultures treated with the empty vector (His/MaxB) (Figure 7). Together, these results suggest that ZO-2 overexpression specifically inhibits the translation of CD1.

To determine whether ZO-2 specifically blocks CD1 synthesis or instead is capable of inhibiting the overall protein synthesis, we proceeded to analyze the effect of ZO-2 transfection on the phosphorylation of mTOR and its targets. mTOR (Sabers et al., 1995), also known as FRAP or RAFT (Brown et al., 1994; Sabatini et al., 1994), is a Ser/Thr protein kinase that plays a major role in regulating cell growth through the control of protein synthesis (Dennis et al., 2001; Fang et al., 2001). When sufficient nutrients are available, mTOR is phosphorylated at Ser2448 via the phosphatidylinositol 3-kinase/Akt signaling pathway (Nave et al., 1999) and is autophosphorylated at Ser2481 (Peterson et al., 2000). mTOR phosphorylates two translational regulatory proteins: the 40S ribosomal protein p70 S6 kinase (p70 S6 K) and the eukaryotic initiation factor 4E-binding protein (4E-BP1) (Gingras et al., 1999). 4E-BP1 binds eukaryotic initiation factor 4E (eIF4E) thereby inhibiting cap dependent translation. Phosphorylation of 4E-BP1 by mTOR disrupts this binding and in consequence activates cap-dependent translation.

As shown in Figure 8A, the phosphorylation of mTOR at Ser2448 and Ser2481 is unaffected by ZO-2 transfection, whereas the system is sensitive to rapamycin, an antifungal agent that specifically inhibits mTOR (Sabers et al., 1995). In a similar manner, mTOR phosphorylation targets p70 S6K and 4E-BP1, exhibit no changes upon ZO-2 transfection but are responsive to rapamycin treatment. In Figure 8B, we used antibodies against the phosphorylated residues Thr389 and Thr421/Ser424 of p70 S6K that are phosphorylated upon mTOR activation (Pullen and Thomas, 1997; Polakiewicz et al., 1998). For the experiment depicted in Figure 8C, an antibody was used that detects bands $\beta$ and $\gamma$, of 4E-BP1, which are phosphorylated to a different degree. Both mock-transfected cells and those transfected with ZO-2 or the empty vector exhibited the same pattern of 4E-BP1 bands, whereas as expected the cells treated with rapamycin show a lower amount of the highly phosphorylated $\gamma$ band and an increased amount of the less phosphorylated $\beta$ band. Together, these results suggest that ZO-2 overexpression does not affect the overall protein synthesis but specifically inhibits the translation of CD1.

Finally, we tested whether the inhibition of CD1 synthesis is associated with an increased phosphorylation of the translation elongation initiation factor eIF2$\alpha$, but we obtained no significant change upon ZO-2 overexpression (data not shown).

ZO-2 Increases CD1 Protein Decay

Next, we decided to explore whether ZO-2 affects the stability of CD1. For this aim [35S]Met pulse-chase analyses of CD1 protein degradation were performed. A steeper rate of decay of CD1 was detectable in cells transfected with ZO-2 (Figure 9). This effect seems to be specific for ZO-2 because transfection with ZO-1 elicits no change in CD1 decay. ZO-2 silencing also had no impact on CD1 turnover, whereas transfection with the ZO-2 amino-terminal segment accelerated CD1 decay similar to full-length ZO-2.

Figure 9. ZO-2 overexpression accelerates CD1 decay. MDCK cells synchronized by serum deprivation for 48 h were transfected with full-length ZO-2, His-NH$_2$-ZO-2 construct; full-length ZO-1, the corresponding empty vectors pGW1, His/MaxB, and pCB6; or ZO-2 siRNA and the negative control NC, and after 6 h they were transferred to CDMEM. After 24 h, the cells received a pulse of [35S]Met/Cys. One hour later, the medium was removed, and the chase proceeded for the indicated times in the presence of cycloheximide.
ZO-2 Overexpression Decreases the Ser9 Inhibitory Phosphorylation of GSK-3β and Represses β-Catenin Target Genes Expression

Degradation of CD1 has been shown to be triggered by its phosphorylation by the Ser/Thr kinase GSK-3β. During S phase, a fraction of GSK-3β localizes to the nucleus, phosphorylates CD1 at Thr286 provoking its nuclear export, ubiquitination, and degradation by the 26S proteosome (Diehl et al., 1998; Gladden and Diehl, 2005). GSK-3β activity is inhibited by phosphorylation at Ser9 via several signal transduction pathways, including Akt, the mitogen-activated protein kinase cascade and mTOR (Cross et al., 1995; Frame and Cohen, 2001). To further analyze the effect of ZO-2 on CD1 degradation, we explored whether ZO-2 transfection affects the phosphorylation of GSK-3β at Ser9. Indeed, ZO-2 overexpression decreases GSK-3β Ser9 phosphorylation (Figure 10A).

GSK-3β is a central player in intracellular Wnt signal transduction (Frame and Cohen, 2001). In the absence of a Wnt signal, GSK-3β present in complex with the adenomatosis polyposis coli protein APC and the scaffold protein Axin phosphorylates cytosolic β-catenin, which is then ubiquitinated and degraded in proteasomes. In the presence of Wnt, β-catenin is not phosphorylated by GSK-3β; hence, β-catenin is translocated to the nucleus where it associates with the T cell factor transcription factor to control the expression of particular target genes that include among others the homeobox gene siamois that regulates the early dorsal axis specification in embryos (Braison et al., 1997).

To further explore the impact of ZO-2 upon GSK-3β function, we analyzed the effect of ZO-2 overexpression in two different Wnt reporter constructs in which luciferase expression is driven either by artificial LEF/TCF binding sites or by the Siamois promoter. Overexpression of ZO-2 in

![Figure 10](https://example.com/figure10.png)

**Figure 10.** ZO-2 overexpression affects GSK-3β function. (A) The phosphorylation of Ser9 in GSK-3β is diminished upon ZO-2 overexpression. MDCK cells synchronized by serum deprivation for 48 h were transfected with ZO-2 or the empty vector, and after 6 h they were transferred to CDMEM. After 24 h, the cells were lysed and processed for immunoblotting with antibodies against GSK-3β and phosphorylated Ser9 of GSK-3β. (B) ZO-2 represses β-catenin/TCF-4–mediated transcription. HEK293 cells were transiently transfected with β-catenin and hTCF-4 expression plasmids and increasing amounts of a HA-ZO-2 expression vector as indicated. β-Catenin/TCF-4 transcriptional activity was measured by co-transfection of TopFlash/FopFlash (left) or Siamois S5/S0 (S5, five TCF-binding sites; S0, all TCF-sites mutated) (right) luciferase reporter gene constructs. (C) ZO-2 specifically represses endogenous axin-2 but not MMP14 and p53 expression in SW480 and MCF-7 cells. SW480 and MCF-7 cells were transiently transfected with 2 μg of pGW1-HA empty vector or pGW1-HA-ZO-2 plasmid. After 12 h, total RNA was isolated to analyze axin-2, MMP14, and p53 expression by quantitative RT-PCR by using gene-specific TaqMan probes. Expression was normalized to β-actin. Values obtained after transfection with empty vector were set to 100%. Presented data are mean values of four independent experiments.
HEK293 and SW480 cells exhibits a dose-dependent repression of both reporter gene constructs (Figure 10B).

Next, we analyzed by qRT-PCR if the endogenous expression of Wnt target genes Axin-2 and MMP14 is affected by ZO-2 overexpression. Interestingly, in both SW480 and MCF-7 cells, whereas Axin-2 is clearly repressed, matrix metalloproteinase 14 was not repressed (Figure 10C). p53, used as a negative control, was not affected.

ZO-2 Overexpression Promotes CD1 Degradation at the Proteosome

In this context, we next treated MDCK cells transfected with the empty vector or ZO-2, with 50 mM LiCl, because Li\(^+\) has been shown to inhibit GSK-3β activity (Klein and Melton, 1996; Hedgepeth et al., 1997). Consistent with our previous results, Li\(^+\) treatment blocked the ZO-2-induced loss of CD1 (Figure 11), confirming the active role of GSK-3β on CD1 degradation. To further study the proteosomal degradation of CD1 triggered by ZO-2, we treated MDCK cells transfected with the empty vector or ZO-2, with the proteosomal inhibitor MG132 (50 μM) and observed an increased amount of CD1 in comparison with untreated cultures (Figure 11). Additionally, we tested whether ZO-2 expression stimulated CD1 degradation at the lysosome. For this purpose, we treated ZO-2-transfected and –untreated cultures with chloroquine, a weak base that accumulates in lysosomes dissipating their acidic pH (Wibo and Poole, 1974). Chloroquine treatment did not block in a statistically significant manner ZO-2-induced loss of CD1 (Figure 11). Together, these experiments reveal that ZO-2 expression increases CD1 degradation at the proteosome.

DISCUSSION

Although the name ZO-2 indicates that this protein is a TJ protein, the work of us and others demonstrated in recent years that ZO-2 is a dual residency protein found at the nucleus and the cell borders depending on the degree of cell–cell contact (Islas et al., 2002; Traeger et al., 2003). Because ZO-2 is conspicuously present at the nuclei of sparse epithelial cells, we have become interested in studying the physiological role of nuclear ZO-2 in these cells. Once we found that ZO-2 associated to TFs and downregulated the activity of reporter genes regulated by promoters under the control of AP-1 sites (Betanzos et al., 2004), we started to explore the transcription of which genes is modulated in vivo by ZO-2. Accordingly, we recently showed that the CD1 gene is down-regulated at the transcription level by ZO-2 via an E-box and the TF c-Myc (Huerta et al., 2007). Other factors known to repress CD1 transcription are for example the lipid phosphatase PTEN (Chung et al., 2006), the tumor suppressor Fhit, (Weiske et al., 2007), and the TFs SIP1 (Mejlvang et al., 2007) and p53 (Rocha et al., 2003).

In this work, we have explored whether ZO-2 overexpression alters the cellular content of CD1 protein. Our results indicate that ZO-2 is able to reduce the protein levels of CD1 in epithelial cells and that this effect is accompanied by a decrease in cell proliferation due to blockade at the G0/G1 phase of the cell cycle, without producing an increase in cellular apoptosis or necrosis.

To our surprise, we were not able to detect any change in the mRNA level triggered by ZO-2 in cells that had been synchronized by serum starvation. These results contrast those previously obtained by us in nonsynchronized cells where the mRNA of CD1 decreases according to the amount of ZO-2 transfected (Huerta et al., 2007). To understand this conundrum, we analyzed the mRNA of CD1 present in nonsynchronized and synchronized cells by serum starvation. Our results indicate that serum-deprived cells that are arrested at G0/G1 exhibit a higher level of CD1 mRNA than nonsynchronized proliferating cells. Thus, we suspect that due to high level of CD1 mRNA found in serum-deprived cells, it is not feasible for ZO-2 to reduce CD1 mRNA in these cells in a significant manner. Interestingly, other studies have revealed cases where CD1 mRNA remains unchanged, whereas CD1 protein content diminishes due to inhibition of translation. For example, 1) in nontransformed intestinal crypt cells, protein kinase C (PKC) stimulation with phorbol 12-myristate 13-acetate does not affect total CD1 mRNA levels at times when CD1 protein is significantly reduced (Hizli et al., 2006). In these cells, activation of PKCα promotes PP2A phosphatase activity that in turn induces the dephosphorylation of the translational repressor 4E-BP1. The hypophosphorylation of 4E-BP1 finally inhibits the translation of CD1 mRNA (Guan et al., 2007). 2) The siRNA knockdown of HMGA1, a TF that promotes cell proliferation by accelerating G1 phase progression, down-
regulates CD1 protein by translational control involving 4E-BP1 (Kolb et al., 2007). 3) The overexpression of PERK, an endoplasmic reticulum transmembrane protein kinase implicated in the mammalian unfolded protein response (UPR) or the activation of UPR with the glycosylation inhibitor tunicamycin, inhibits CD1 synthesis without affecting CD1 mRNA level (Brewer et al., 1999; Brewer and Diehl, 2000). PERK blocks CD1 translation by increasing the phosphorylation of the translation elongation initiation factor eIF2α (Brewer and Diehl, 2000) and by augmenting the degradation of CD1 at the proteasome. Apparently, this degradation is dependent upon eIF2α phosphorylation (Raven et al., 2008). In a somewhat similar manner, 15-deoxy-Δ12,14-prostaglandin J2 down-regulates CD1 protein by stimulating eIF2α phosphorylation (Campos et al., 2002). 4) A more extreme case is found in rat fibroblasts in which the induced expression of Ras, increases CD1 mRNA level and at the same time decreases CD1 protein synthesis and augments the rate of CD1 degradation at the proteasome (Shao et al., 2000).

Here, we have found that ZO-2 transfection accelerates CD1 turnover and promotes CD1 degradation at the proteasome in synchronized cells. In this regard, others have found that retinoic acid that suppresses cell growth at the G1/S cell cycle transition, triggers a decline in CD1 protein, not due to a decreased mRNA expression but to an increased CD1 degradation at the proteasome (Langenfeld et al., 1997; Spinella et al., 1999). Additionally, the chemotherapeutic agents curcumin, a diferuloylmethane, and GL331, a podophyllotoxin-derived compound, down-regulate the expression of CD1 protein by reducing mRNA expression, inhibiting CD1 promoter-dependent gene expression, and inducing CD1 proteolysis at the proteasome (Lin et al., 2001; Mukhopadhyay et al., 2002; Srivastava et al., 2007).

Because a critical step leading to CD1 degradation involves its phosphorylation at Thr286 by GSK-3β, we studied the impact of ZO-2 overexpression on GSK-3β function. Our results indicate that ZO-2 has a repressive effect not only on an artificial LEF/TCF construct but also on a natural target of the β-catenin signaling pathway, such as Siamois. These results together with our previous observation on the CD1 promoter (Huerta et al., 2007) suggest that ZO-2 modulates, in a context-specific manner, the expression of genes involved in cell proliferation and differentiation.

Here, we have also demonstrated that ZO-2 enters the nucleus at the late G1 phase and leaves the nucleus when the cell is in mitosis. This explains why in confluent quiescent cells almost no nuclear ZO-2 staining is detected, whereas in sparse proliferating cells ZO-2 is conspicuously present at the nuclei. The nuclear exit of ZO-2 during mitosis could speculatively occur as a response to the requirement of ZO-2 at the novel plasma membrane established between the dividing cells. With regard to CD1, we found that in MDCK cells the protein enters the nucleus in early G1 and exits the nuclei at the S phase as had been reported previously in fibroblasts (Baldin et al., 1993; Diehl et al., 1998).

In summary, these results can lead us to propose a model in which ZO-2 enters the nucleus at the late G1 phase, whereas GSK-3β is imported to the nucleus immediately after the G1/S transition (Figure 12). ZO-2, through a yet undefined mechanism, decreases the inhibitory phosphorylation of GSK-3β at Ser9. Activated GSK-3β phosphorylates cyclin D1 at Thr286 triggering CD1 nuclear export and degradation at the proteasome.

ACKNOWLEDGMENTS

We thank the technical help of Victor Hugo Rosales García and Jose de la Luz Díaz Chávez. This work was supported by grant 45691-Q from the Mexican Council for Science and Technology (Consejo Nacional de Ciencia y Tecnología [CONACYT]). R. T. and M. H. were recipients of doctoral fellowships from CONACYT (166727 and 159492). The work of O. H. was supported by a grant of the Deutsche Forschungsgemeinschaft (FOR721, HU881/4-1).

REFERENCES


Figure 12. Schematic model depicting the subcellular localization of ZO-2, CD1, and GSK-3β during the cell cycle. At the early stages of G1, CD1 enters the nucleus and initiates cell cycle progression toward the S phase. At the later stages of G1, ZO-2 is imported into the nucleus. GSK-3β enters the nucleus at the S phase, and ZO-2 decreases the inhibitory phosphorylation of GSK-3β at Ser9 by a yet unknown pathway. Activated GSK-3β phosphorylates cyclin D1 at Thr286, triggering CD1 nuclear export, ubiquitination, and degradation by the 26S proteasome. At mitosis, ZO-2 leaves the nucleus and is speculatively recruited to the emerging cell borders of the dividing cells. Time indicated in purple corresponds to time after nocodazole washout, whereas time indicated in brown represents time after mimosine washout.


R. Tapia et al.


